Related Experiment Videos

Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference

Raymond C Rosen1, Graham Jackson, John B Kostis

  • 1University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ 08854, USA. rosen@umdnj.edu

Current Urology Reports
|October 21, 2006
PubMed

Insights

Erectile dysfunction (ED) is linked to cardiovascular disease. Updated guidelines (Princeton II) emphasize risk assessment and management, noting sexual activity is safe for most patients with ED.

Area of Science:

  • Cardiology
  • Urology
  • Sexual Medicine

Background:

  • Erectile dysfunction (ED) is increasingly recognized as a potential indicator of underlying cardiovascular disease (CVD).
  • Existing guidelines (Princeton I) provided a framework for assessing cardiac risk in patients with ED.
  • New data and phosphodiesterase type 5 inhibitors (PDE5i) necessitated guideline updates.

Purpose of the Study:

  • To update guidelines for the assessment and management of cardiovascular risk in patients with ED.
  • To incorporate recent findings on the ED-CVD link and new PDE5i.
  • To provide guidance on managing patients with ED, including those with acute coronary syndromes.

Main Methods:

  • Review of current data linking ED and cardiovascular risk factors.
  • Evaluation of the safety and efficacy of PDE5 inhibitors (vardenafil, tadalafil).
  • Development of updated risk stratification and management strategies.

Main Results:

  • Sexual activity is generally safe for the majority of patients with ED.
  • Comprehensive cardiovascular risk factor assessment is crucial for all ED patients.
  • Risk factor modification, including lifestyle changes, is strongly recommended.

Conclusions:

  • Updated guidelines (Princeton II) offer a refined approach to managing ED patients with cardiovascular concerns.
  • Careful assessment and risk factor modification are key.
  • Specific guidance is provided for managing acute coronary syndromes and drug interactions in ED patients.

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...